Clinical review of subcutaneous semaglutide for obesity. (28th December 2021)

• Record Type: Journal Article
• Authors: Phillips, Anna; Clements, Jennifer N.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 47:Number 2(2022)
• Page Start: 184
• Page End: 193
• Publication Date: 2021-12-28
• Subjects: GLP‐1 receptor agonist -- glucagon‐like peptide‐1 -- obesity -- overweight -- semaglutide; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13574
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: The purpose of this review paper is to review the efficacy and safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon‐like peptide‐1 receptor agonist for obesity management. Methods: A MEDLINE search (1970 to June 2021) was conducted to identify Phase 3 trials of subcutaneous semaglutide for obesity management. Published Phase 3 trials from The Semaglutide Treatment Effect in People with obesity (STEP) program were reviewed and summarized. Results and discussion: Based on four Phase 3 trials, subcutaneous semaglutide as 2.4 mg once weekly was compared in efficacy and safety among 5000 randomized participants who were overweight or had obesity. A change in body weight from baseline to end of study was the primary outcome in the STEP program. Participants who received semaglutide had a dose‐dependent reduction in body weight from baseline, compared to placebo. Higher percentages of participants had 5%–10% weight reduction from baseline when receiving subcutaneous semaglutide. The patient population was mainly middle‐aged female participants with Class II obesity. Additional studies are needed, especially active‐comparator trials, to determine the efficacy and safety of semaglutide in a diverse patient population. What is new and conclusion: Subcutaneous semaglutide is another available option as adjunct therapy to lifestyle modifications for people who are overweight or have obesity based on body weight and body mass index. It resulted in more weight reduction than placebo with gastrointestinal adverse events being the most common safety concerns. Clinical utilization of subcutaneous semaglutide will be determined, as insurance coverage will be a limitation for this new medication. Abstract : A MEDLINE search (1970 to June 2021) was conducted to identify Phase 3 trials of subcutaneous semaglutide for obesity management . Published Phase 3 trials from The Semaglutide Treatment Effect in People with obesity (STEP) program were reviewed and summarized in this article. More than 5000 participants were enrolled in the STEP program to evaluate subcutaneous semaglutide, titrated to maximum dose of 2.4 mg per week, versus placebo. All participants received counseling on daily caloric reduction, physical activity and behavioral modifications. As a once‐weekly injection for obesity, semaglutide has resulted in weight‐loss similar to bariatric surgery . Gastrointestinal events are common for the safety profile of semaglutide, which is similar to other glucagon‐like peptide‐1 receptor agonists.